Literature DB >> 23407702

Clinical characteristics and outcome of multiple sclerosis in Korea: does multiple sclerosis in Korea really differ from that in the Caucasian populations?

Su-Hyun Kim1, So-Young Huh, Woojun Kim, Min Su Park, Suk-Won Ahn, Joong-Yang Cho, Byung Jo Kim, Ho Jin Kim.   

Abstract

BACKGROUND: Multiple sclerosis (MS) in Asia is thought to have different clinical characteristics from MS in Western countries; however, previous studies in Asia were performed without properly differentiating neuromyelitis optica (NMO) from MS.
OBJECTIVES: To evaluate the clinical characteristics of MS in Korea after careful exclusion of potential explanations other than MS, particularly NMO spectrum disorder (NMOSD).
METHODS: This study is a retrospective review of consecutive MS patients attending five referral hospitals in Korea. All patients' MS diagnoses were re-evaluated.
RESULTS: Of the 105 patients, 70 were female and 35 were male. The mean age of onset was 30.4 years and the mean disease duration was 5.4 years. On initial magnetic resonance imaging (MRI), 58% and 64% fulfilled the criteria for dissemination in space for the 2005 and 2010 McDonald criteria, respectively. Spinal cord lesions were observed in 78% of patients, primarily present as multiple small lesions with a mean length of 0.9 vertebral segments. The median time from disease onset to an Expanded Disability Status Scale 6 was 20 years.
CONCLUSIONS: After careful exclusion of NMOSD, we found that the clinical pattern of MS in Korea does not fundamentally differ from that seen in Western countries.

Entities:  

Keywords:  Asia; Korea; Multiple sclerosis; beta-interferon; clinical characteristics; epidemiology; neuromyelitis optica; optic-spinal multiple sclerosis

Mesh:

Substances:

Year:  2013        PMID: 23407702     DOI: 10.1177/1352458513477712

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  7 in total

Review 1.  MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.

Authors:  Ulrike W Kaunzner; Susan A Gauthier
Journal:  Ther Adv Neurol Disord       Date:  2017-05-12       Impact factor: 6.570

Review 2.  Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics.

Authors:  DeRen Huang
Journal:  Neurosci Bull       Date:  2015-12       Impact factor: 5.203

3.  Utility of the rio score and modified rio score in korean patients with multiple sclerosis.

Authors:  Jae-Won Hyun; Su-Hyun Kim; In Hye Jeong; Suk-Won Ahn; So-Young Huh; Min Su Park; Young In Eom; In Soo Joo; Joong-Yang Cho; Eun Bin Cho; Ju-Hong Min; Byoung Joon Kim; Nam-Hee Kim; Jeeyoung Oh; Kee Duk Park; Ho Jin Kim
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

4.  Multiple sclerosis in malaysia: demographics, clinical features, and neuroimaging characteristics.

Authors:  S Viswanathan; N Rose; A Masita; J S Dhaliwal; S D Puvanarajah; M H Rafia; S Muda
Journal:  Mult Scler Int       Date:  2013-12-26

5.  Multiple Sclerosis Patients with Markedly Low Intrathecal Antibody Response in Sri Lanka.

Authors:  S M K Gamage; I Wijeweera; S B Adikari; Katharina Fink; Jan Hillert; Anna Fogdell-Hahn; H M A Sominanda
Journal:  Mult Scler Int       Date:  2018-02-28

Review 6.  Spinal Cord Involvement in MS and Other Demyelinating Diseases.

Authors:  Mariano Marrodan; María I Gaitán; Jorge Correale
Journal:  Biomedicines       Date:  2020-05-22

Review 7.  Model-informed assessment of ethnic sensitivity and dosage justification for Asian populations in the global clinical development and use of cladribine tablets.

Authors:  Alain Munafo; Nadia Terranova; Dandan Li; Ping Liu; Karthik Venkatakrishnan
Journal:  Clin Transl Sci       Date:  2021-10-26       Impact factor: 4.689

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.